HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Research analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Ocular Therapeutix in a report issued on Tuesday, March 4th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter, down from their prior estimate of ($0.24). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.18) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The business had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million.

Ocular Therapeutix Trading Up 2.7 %

Ocular Therapeutix stock opened at $7.34 on Thursday. Ocular Therapeutix has a 52 week low of $4.06 and a 52 week high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The stock has a market capitalization of $1.15 billion, a P/E ratio of -5.56 and a beta of 1.22. The stock has a 50-day simple moving average of $7.78 and a 200 day simple moving average of $8.88.

Institutional Investors Weigh In On Ocular Therapeutix

Several institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new position in Ocular Therapeutix during the fourth quarter valued at approximately $28,000. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix during the fourth quarter valued at approximately $43,000. Mirae Asset Global Investments Co. Ltd. raised its position in Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,015 shares in the last quarter. AlphaQuest LLC acquired a new position in Ocular Therapeutix during the fourth quarter valued at approximately $53,000. Finally, Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix during the third quarter valued at approximately $70,000. 59.21% of the stock is currently owned by institutional investors.

Insider Transactions at Ocular Therapeutix

In other news, insider Donald Notman sold 6,301 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the sale, the insider now owns 204,563 shares in the company, valued at $1,603,773.92. The trade was a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,895 shares of company stock worth $283,772 over the last quarter. Company insiders own 3.50% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.